Curis, Inc. (NASDAQ:CRIS) Files An 8-K Results of Operations and Financial Condition

Curis, Inc. (NASDAQ:CRIS) Files An 8-K Results of Operations and Financial Condition
Item 2.02.


CURIS INC Exhibit
EX-99.1 2 tm1921869d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Curis Reports Third Quarter 2019 Financial Results – Management to host conference call today at 8:30 a.m. ET -LEXINGTON,…
To view the full exhibit click here

Story continues below

About Curis, Inc. (NASDAQ:CRIS)

Curis, Inc. is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Its product pipeline includes CA-170, which is an oral small molecule drug candidate; CA-4948, which is an oral small molecule drug candidate that is designed to inhibit the interleukin-1 receptor-associated kinase 4 (IRAK4) kinase; Erivedge, which is an orally bioavailable small molecule, and is designed to selectively inhibit the Hedgehog signaling pathway; CUDC-427, which is an oral, small molecule Smac mimetic that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins, and CUDC-305, which is an oral HSP90 inhibitor for the development in advanced lung cancer.

An ad to help with our costs